• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

0.2450 -0.0350 (-12.50%)
Delayed Quote Updated: 3:56 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 238,462
Open 0.2800
Bid (Size) 0.2200 (500)
Ask (Size) 0.3841 (200)
Prev. Close 0.2800
Today's Range 0.2286 - 0.2831
52wk Range 0.2286 - 4.340
Shares Outstanding 15,886,576
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 Operational Highlights and Advances AI-Driven Oncology Pipeline
November 18, 2026
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Reports Third Quarter 2026 Financial Results and Provides Business Updates
November 18, 2026
From Lantern Pharma Inc.
Via Business Wire

Performance

52-Week Range 94.4% below 52-week high
0.2450
0.2352W Low 4.3452W High
1 Week 50.0% below 1-week high
0.231W Low 0.491W High

Lantern Pharma Inc. - Common Stock (LTRN) traded between $0.23 and $4.34 over the past 52 weeks and last traded at $0.24, 94.4% below its 52-week high. Over the past week it ranged between $0.23 and $0.49.

Past 12 Months
-37.0%
-64.2%
-89.5%
-93.0%
-92.1%
-91.8%
1W -$0.14
1M -$0.44
3M -$2.09
6M -$3.25
YTD -$2.86
1Y -$2.75

LTRN was -91.8% over the past year, -93.0% over six months, -92.1% year to date, -37.0% in the last week.

12 Months vs Market
LTRN
-91.8%
DIA
+5.0%
SPY
+5.7%
QQQ
+3.9%
IWM
+12.0%

Over the past 12 months LTRN returned -91.8% versus DIA (Dow) +5.0%, SPY (S&P 500) +5.7%, QQQ (Nasdaq 100) +3.9% and IWM (Russell 2000) +12.0%.

Volume & Liquidity 0.96× 3-mo avg
Today 238,462 3-mo avg 248.9K
1W
196.2K
1M
189.0K
3M
248.9K
6M
206.0K
YTD
304.8K
1Y
278.7K

LTRN most recently traded 238,462 shares against a 3-month average daily volume of 248.9K.

More News

Read More
MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Publishes Phase 1a Glioblastoma Data, Advances LP-184 Combination Therapy Toward Phase 1b/2a Trial
November 10, 2026
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Announces Peer-Reviewed Publication of Phase 1a LP-184 Data in Recurrent Glioblastoma, Supporting a Phase 1b/2a Combination Trial with Spironolactone
November 10, 2026
From Lantern Pharma Inc.
Via Business Wire
News headline image
Powering the AI Economy: New to The Street Show #776 Premieres Tonight on Bloomberg Television
October 17, 2026
From New to The Street
Via ACCESS Newswire
News headline image
New to The Street Show 775 Premieres Tonight on Bloomberg Television Across the United States, Latin America, MENA and Southeast Asia, Featuring American Fusion, HPB, T-REX Acquisition Corp. and SyncMeOn
October 10, 2026
From New to The Street
Via ACCESS Newswire
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present at ThinkEquity Conference on Oct. 15
October 08, 2026
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026
October 08, 2026
From Lantern Pharma Inc.
Via Business Wire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Receives Taiwan Approvals to Advance Phase 2 HARMONIC(TM) Trial
October 07, 2026
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
October 07, 2026
From Lantern Pharma Inc.
Via Business Wire
NetworkNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Closes $4 Million Registered Direct Offering
October 01, 2026
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
September 30, 2026
From Lantern Pharma Inc.
Via Business Wire
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Announces $4 Million Registered Direct Offering
September 29, 2026
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering
September 29, 2026
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global
September 26, 2026
From New to The Street
Via ACCESS Newswire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present Open-Medicine AI Growth Plan, Live Platform Demo in Webinar
September 23, 2026
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
September 23, 2026
From Lantern Pharma Inc.
Via Business Wire
MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives USPTO Notice of Allowance for LP-284 Blood Cancer Treatment Patent
September 22, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas
September 22, 2026
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
September 19, 2026
From New to The Street
Via ACCESS Newswire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) to Host Webinar on Open-Medicine AI Platform, Business Model and Development Roadmap
September 17, 2026
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23
September 17, 2026
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street Show 771 Airs Today on Bloomberg, Featuring Bill Mobley, Panna Sharma, Phillip Toppino and Dr. Kelley Gurley
September 12, 2026
From New to The Street
Via ACCESS Newswire
News headline image
New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST)
September 05, 2026
From New to The Street
Via ACCESS Newswire
News headline image
New to The Street Broadcasting Today at 6:30 PM EST on Bloomberg Television Across the U.S., Latin America and MENA-Featuring FreeCast (NASDAQ: CAST), Metaterra Holdings (MTHI) and SafeSpace Global (SGCC)
August 29, 2026
From New to The Street
Via ACCESS Newswire

Frequently Asked Questions

Is Lantern Pharma Inc. - Common Stock publicly traded?
Yes, Lantern Pharma Inc. - Common Stock is publicly traded.
What exchange does Lantern Pharma Inc. - Common Stock trade on?
Lantern Pharma Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lantern Pharma Inc. - Common Stock?
The ticker symbol for Lantern Pharma Inc. - Common Stock is LTRN on the Nasdaq Stock Market
What is the current price of Lantern Pharma Inc. - Common Stock?
The current price of Lantern Pharma Inc. - Common Stock is 0.2450
When was Lantern Pharma Inc. - Common Stock last traded?
The last trade of Lantern Pharma Inc. - Common Stock was at 11/20/26 03:56 PM ET
What is the market capitalization of Lantern Pharma Inc. - Common Stock?
The market capitalization of Lantern Pharma Inc. - Common Stock is 3.89M
How many shares of Lantern Pharma Inc. - Common Stock are outstanding?
Lantern Pharma Inc. - Common Stock has 4M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap